The Gastrointestinal Cancers Symposium will focus on multidisciplinary care that will highlight cutting-edge strategies, innovations, and research in gastrointestinal cancer care. Renowned faculty from around the world will offer their valuable perspectives on a wide array of topics covering cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus.
- Continuing Medical Education Certificate - available for physicians who would like to receive CME credits for their participation at the Symposium.
- Certificate of Participation – all other attendees may request a Certificate of Participation after recording their session participation. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted.
- Certificate of Attendance – Attendees can download a Certificate of Attendance from the Attendee Resource Center if they need a record of their attendance at the Symposium but do not require documentation for continuing education purposes. Please note that this certificate does not award any continuing education credits.
For instructions on how to claim credit and access certificates, please see the ‘Symposium Feedback and Credit Claim Instructions’ section.
Symposium Feedback and Credit Claim Instructions
Every participant is encouraged to submit a Symposium Feedback Form, provide session ratings, and access certificates for the Symposium through the iPlanner app or CE Portal. Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future meetings.
- To provide feedback on a specific session
- Download the iPlanner app
- Select a session by searching by time or track
- Select “Rate This Session” to submit feedback on each session you attend
- To access certificates and claim credit
- Log in to the CE Portal using your ASCO.org username and password
- Select the appropriate meeting and your role
- Select "CME Certificate" to claim credit and download the certificate
- To give overall feedback on the meeting
- Log in to the CE Portal using your ASCO.org username and password
- Select "Provide Meeting Feedback" to submit your feedback on the symposium
To receive ABIM MOC points, participants must submit their Symposium Feedback Form and claim their CME credits in the CE Portal for the Symposium by February 21, 2019. Once both of these steps are complete, ASCO will transmit all information to ABIM on the participant’s behalf.
Accreditation and Designation Statement
In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA Credit Designation Statement - Physicians
The American Society of Clinical Oncology designates this live activity for a maximum of 21.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA/NCCPA Credit Designation Statement – PAs
PAs may claim a maximum of 21.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted.
This symposium is designed for physicians and researchers interested in the prevention, screening, evaluation, and management of gastrointestinal cancers, including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.
This symposium may also benefit nurses, pharmacists, physician assistants, and other health care professionals involved in clinical cancer care and cancer research..
Educational Needs Statement
The treatment of gastrointestinal (GI) cancers requires a broad range of knowledge regarding new and established therapies, including newly approved immunotherapies, effective use of biomarkers and targeted therapies, to use of multimodality therapy including surgery, cytotoxic chemotherapy and radiation in the neoadjuvant and adjuvant settings. It is a complex landscape that requires continuous education. Unfortunately, many clinicians report feeling underprepared in this rapidly changing environment. Despite treating patients with immunotherapy agents, fewer than one-quarter of responding clinicians in a recent survey reported having deep familiarity with checkpoint inhibitors. It has been well-documented in the colorectal cancer (CRC) setting and others, that genetic and molecular testing is underused, despite guidelines. Underuse of appropriate therapy in pancreatic, gastroesophageal, and other GI cancers has also been noted, regardless of the modality. Significant disparities in delivery of care and clinical outcomes also persist across GI disease states and stages. This year’s GI Symposium seeks to fill gaps not only in the science of precision medicine, but also in the personalization of medicine for the individual patient.
Upon participation in this activity, attendees will be better able to
- Collaborate across different specialties and with all members of the oncology care team to deliver effective and patient-centered treatment for patients with gastrointestinal cancers;
- Examine the effects of healthcare disparities on the outcomes of patients with gastrointestinal cancers;
- Discuss the relationship between biology, biomarkers, and response in novel therapeutics, including targeted and immune-oncology agents, based on current evidence and how this translates to research and, ultimately, clinical care;
- Consider the benefits and challenges of multimodality therapy in a number of GI malignancies, including appropriate patient selection and optimal treatment sequencing;
- Compare and contrast the disease characteristics that indicate difference surgical options to determine the best approach and best sequencing with other therapies, where indicated, based on current evidence in the treatment of each patient with gastrointestinal cancer.
- Review where novel and advanced diagnostic strategies can inform more precise treatment of patients with gastrointestinal cancers based on current evidence, including novel biomarker technologies and novel imaging techniques.
Disclaimer and Unlabeled Usage Statement
The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters. Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.
ASCO and Conquer Cancer gratefully awknowledge the following companies for their support of the 2019 Gastrointestinal Cancers Symposium: